home

Recipharm AB: Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India

EVENTSbusinesswire2016-04-20 13:58 Read   115

Recipharm AB (publ) (“Recipharm” or the “Company”) announces today that it has signed two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.

Valeant CEO Deposed for at Least Nine Hours by Senate Committee

EVENTSbloomberg2016-04-20 13:38 Read   69

Valeant Pharmaceuticals International Inc. outgoing Chief Executive Officer Mike Pearson was deposed for at least nine hours on Monday by a Senate committee that’s investigating his company’s drug pricing practices, ahead of a public hearing later this month.

MS patent challenges put billions in Biogen sales at risk

EVENTSfiercepharma2016-04-20 13:23 Read   75

Biogen, already battling in a patent fight over multiple sclerosis star Tecfidera, has run into another challenge--this time with fellow MS treatment Tysabri.

Exclusive: Lonza in bid to acquire Catalent - sources

EVENTSreuters2016-04-20 13:09 Read   71

Swiss specialty chemicals and life sciences company Lonza Group AG (LONN.S) has offered to acquire U.S. drug delivery technology company Catalent Inc (CTLT.N), three people familiar with the matter said this week.

Roche sues Intas Pharma over Mircera anaemia drug patent

EVENTSeconomictimes2016-04-20 13:04 Read   139

MUMBAI: Swiss biotechnology giant Roche has sued Ahmedabad-based drug maker Intas Pharmaceuticals in Delhi High Court, alleging infringement of its patent rights over Mircera, an injectable brand used to treat patients with anaemia in chronic kidney-related ailments. 

Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor

EVENTSFIRST WORD2016-04-20 10:25 Read   74

Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Unfazed by a tough market, PhaseRx, Gemphire go for IPOs

EVENTSfiercebiotech2016-04-20 09:53 Read   76

Two biotechs are seeking to float in two separate offerings worth $90 million as both look to shrug off the bad luck of other companies that had to ditch their IPOs in the past week.

Bioclinica and ArisGlobal Partner to Transform Pharmacovigilance Model

EVENTSyahoo2016-04-20 09:38 Read   67

Bioclinica®, Inc., a specialty clinical trials technology and services provider, today announced the selection of ArisGlobal's Safety Cloud as the preferred safety platform for its pharmacovigilance services.

SANOFI INVESTS €300 MILLION TO EXPAND BIOLOGICS SITE IN BELGIUM

EVENTSsanofi2016-04-20 09:29 Read   69

Sanofi Invests €300 Million To Expand Biologics Site in Belgium;Additions to existing site will support production of monoclonal antibodies

DalCor Pharmaceuticals Completes $150 Million Financing

EVENTSprnewswire2016-04-20 09:21 Read   66

Proceeds to Fund Phase 3 Trial of Dalcetrapib in Genetically Distinct Patients with Acute Coronary Syndrome (ACS)

Bavarian Nordic A/S Completes a Private Placement at Market Price

EVENTSglobenewswire2016-04-20 09:11 Read   75

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

BMA highlights concerns over NHS private providers

EVENTSpharmatimes2016-04-19 17:23 Read   71

More than two-thirds of doctors are uncomfortable with the use of private providers for NHS services, according to a new report by the British Medical Association.